Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 8/20 | 0.45 |
| ▸ | NPC1 | O15118 | 6/20 | 0.44 |
| ▸ | CASP6 | P55212 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL992135 | 0.90 | POLB (0.61) | TDP1MEN1KMT2APOLBRAB9A | |
| SCHEMBL992344 | 0.88 | KMT2A (0.47) | TDP1MEN1KMT2AHTTPOLB | |
| SCHEMBL1079065 | 0.86 | ALDH1A1 (0.57) | TDP1MEN1KMT2APOLBRAB9A | |
| SCHEMBL11555049 | 0.83 | KMT2A (0.56) | TDP1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL993875 | 0.83 | KMT2A (0.56) | TDP1MEN1KMT2ARAB9ANPC1 | |
| SCHEMBL991587 | 0.83 | ALDH1A1 (0.52) | TDP1MEN1KMT2APOLBRAB9A | |
| SCHEMBL991703 | 0.82 | MEN1 (0.55) | TDP1MEN1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL12950400 | 0.81 | HTT (0.48) | TDP1HTTPOLBRAB9ANPC1 | |
| SCHEMBL19821665 | 0.81 | MEN1 (0.66) | TDP1MEN1KMT2APOLBRAB9A | |
| SCHEMBL991053 | 0.81 | KMT2A (0.51) | TDP1MEN1KMT2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | claimed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | claimed |
| EP-2641906-B1 | Tofa analogs useful in treating dermatological disorders or conditions | DERMIRA CANADA INC (US) | 2015-04-22 | — | — | EP | claimed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | claimed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | claimed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | claimed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | claimed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | claimed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | claimed |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | UNIV CALIFORNIA (US) | 2026-02-05 | — | — | US | disclosed |
| WO-2022005871-A1 | METHODS OF TREATING SARS-COV-2 INFECTION USING INHIBITORS OF LIPOGENESIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-01-06 | — | — | WO | disclosed |
| US-9782382-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA (CANADA) INC (US) | 2016-11-24 | — | — | US | disclosed |
| US-9434718-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-8884034-B2 | TOFA analogs useful in treating dermatological disorders or conditions | DERMIRA (CANADA), INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2641906-A1 | Tofa analogs useful in treating dermatological disorders or conditions | Dermira (Canada), Inc. (US) | 2013-09-25 | — | — | EP | disclosed |
| EP-2451796-B1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | DERMIRA CANADA INC (US) | 2013-04-17 | — | — | EP | disclosed |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2012-08-16 | — | — | US | disclosed |
| EP-2451796-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Dermira (Canada), Inc. (CA) | 2012-05-16 | — | — | EP | disclosed |
| WO-2011005660-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | Valocor Therapeutics, Inc. (CA) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160338988-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | TDP1 3363/4885MEN1 4056/4885KMT2A 2716/4885 |
| US-20120208807-A1 | TOFA ANALOGS USEFUL IN TREATING DERMATOLOGICAL DISORDERS OR CONDITIONS | FAH, CUTA, ALOX5AP | TDP1 3323/4885MEN1 3929/4885KMT2A 3026/4885 |
| US-20260034091-A1 | Compositions and Methods for Treating Metabolic Disorders | LIPC, GPR119, PNLIP | TDP1 4755/4885MEN1 3713/4885KMT2A 3144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.